EU COVID-19 Rapid Antigen Tests Common List Inclusion of YHLO GLINE-2019-nCoV Ag
After being successfully granted official approval by the German PEI, YHLO’s rapid antigen test product GLINE-2019-nCoV Ag is officially listed on the EU COVID-19 Rapid Antigen Tests Common List on 8th December, 2021.
Regulated by the EU Health Security Committee (HSC), this common list is intended to recognize COVID-19 rapid antigen tests which are considered appropriate for use in the context of the situations described in the Council Recommendation, that are in line with EU countries’ testing strategies after series of comprehensive evaluations.
The recognition from the HSC common list is a credible proof that, YHLO’s rapid antigen test product is well-qualified to be applied in the COVID-19 pandemic control measure. Just as GLINE-2019-nCoV Ag can effectively detect the recently-emerged SARS-CoV-2 variant Omicron, as well as other Variants of Concern, YHLO’s product is capable of facing upcoming challenges with deliberate product design and assured quality.
YHLO is always pursuing to provide better solutions for global public health. With the mission of “Focus on healthcare, better life with technology”, YHLO will continue to provide reliable, high-quality healthcare innovations and services worldwide to improve human well-being.
Attachments:
Previous
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
